Echocardiography is an important tool to evaluate target organ damage in patients with hypertension, which is essential to estimate their cardiovascular risk. 1,2 It can detect parameters that correlate independently with cardiovascular events, such as alterations in left ventricular (LV) mass (LVM), LV geometric pattern, left atrial (LA) size, and LV diastolic function. 2-6 LV hypertrophy (LVH) is a frequent finding among patients with hypertension, affecting 12% of patients with a stage I hypertension (systolic blood pressure (SBP) of 140-159 mm Hg) and 20% with stage II hypertension (SBP over 160 mm Hg). 1,7 An increase of 39 g/m 2 in LVM is associated with a 40% rise on incidence of major cardiovascular events, independently of traditional risk factors. 8 LV geometry, based on LVM indexed for body surface area and relative wall thickness (RWT), helps categorize LVH patterns, which have distinct prognostic information. 9 LVH is associated with diastolic dysfunction, 10 and LA size is a marker of severity and duration of diastolic dysfunction, which has an independent association with cardiovascular outcomes. 11 Antihypertensive treatment reduces cardiovascular events. 12 Improvement in echocardiographic parameters of hypertensive target organ damage is seen with BP reduction treatment in patients with stage II hypertension. 13, 14 However, this is not so well studied in less severe stage I hypertension. 15 Meta-analysis have suggested that intensive antihypertensive treatment in patients with prehypertension and hypertension stage I reduces cardiovascular events, 16 which has been confirmed in the recent SPRINT trial. 17 
Echocardiography is an important tool to evaluate target organ damage in patients with hypertension, which is essential to estimate their cardiovascular risk. 1, 2 It can detect parameters that correlate independently with cardiovascular events, such as alterations in left ventricular (LV) mass (LVM), LV geometric pattern, left atrial (LA) size, and LV diastolic function. [2] [3] [4] [5] [6] LV hypertrophy (LVH) is a frequent finding among patients with hypertension, affecting 12% of patients with a stage I hypertension (systolic blood pressure (SBP) of 140-159 mm Hg) and 20% with stage II hypertension (SBP over 160 mm Hg). 1, 7 An increase of 39 g/m 2 in LVM is associated with a 40% rise on incidence of major cardiovascular events, independently of traditional risk factors. 8 LV geometry, based on LVM indexed for body surface area and relative wall thickness (RWT), helps categorize LVH patterns, which have distinct prognostic information. 9 LVH is associated with diastolic dysfunction, 10 and LA size is a marker of severity and duration of diastolic dysfunction, which has an independent association with cardiovascular outcomes. 11 Antihypertensive treatment reduces cardiovascular events. 12 Improvement in echocardiographic parameters of hypertensive target organ damage is seen with BP reduction treatment in patients with stage II hypertension. 13, 14 However, this is not so well studied in less severe stage I hypertension. 15 Meta-analysis have suggested that intensive antihypertensive treatment in patients with prehypertension and hypertension stage I reduces cardiovascular events, 16 which has been confirmed in the recent SPRINT trial. 17 It is not clear whether these benefits are associated with cardiac adaptation mechanisms evaluated by echocardiographic examination.
The aim of the present study was to evaluate the effect of antihypertensive treatment with either chlorthalidone/ amiloride or losartan for 18 months in patients with stage I hypertension on LVM estimated by echocardiography. Secondary objectives were to assess the effect of this treatment on LA volume and diastolic parameters, and the prevalence of normal diastolic function and normal LV geometry. For this, we conducted an echocardiographic cohort study nested in the PREVER-treatment study.
METHODS

Study design
This study corresponds to an ancillary echocardiographic investigation performed at a single center of the PREVERtreatment study (Figure 1) . Population, methods, and results of the PREVER-treatment study are described in detail elsewhere. 18 Briefly, it was a multicenter randomized double-blind controlled trial of chlorthalidone along with amiloride vs. losartan for the management of stage I hypertension in 655 participants aged 30-70 years, with a follow up of 18 months. Treatment with diuretics compared with losartan yielded a greater reduction in BP with less add-on antihypertensive medication. The study was approved by the local institutional review board and written informed consent was obtained from all participants.
Population
All participants from the Hospital de Clínicas de Porto Alegre (HCPA) center of the PREVER-treatment study were invited to participate of the ancillary echocardiographic study, where transthoracic echocardiography was performed at baseline and after 18 months of treatment. Exclusion criteria included, beyond the clinical trial criteria, completion of only one echocardiographic examination or image quality unsuitable for reading.
Interventions
In summary, all eligible participants of the PREVERtreatment study were submitted to a pre-enrollment lifestyle intervention phase (counseling on weight loss, dietary sodium reduction, adoption of a DASH-type diet, physical activity, and smoking cessation). Those participants whose BP remained inadequately controlled (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) after 3 months of lifestyle intervention were randomly assigned in a 1:1 ratio to a chlorthalidone/ amiloride combination pill or to losartan. Initial doses of the 2 study drugs were 12.5/2.5 mg for the chlorthalidone/ amiloride combination pill and 50 mg for losartan. Every 3 months there was a reassessment and if necessary treatment was scaled up according to the protocol. The final visit occurred after 18 months of follow-up.
Echocardiographic study
All echocardiographic examinations were performed using the same equipment (Envisor C HD or HD 11, Philips) with a standard multifrequency sectorial transducer by 2 trained cardiologists blinded to clinical trial information and treatment allocation. Images were acquired following a standardized protocol. Cine loops and static images of 3 consecutive beats were recorded of standard 2D, M-mode, Doppler, and tissue Doppler echocardiographic views and were digitally recorded for central reading.
Echocardiographic studies were blindly read by a single physician using a dedicated workstation (Image Arena version 4, TomTec, Germany). Measurements were performed in accordance with international society guidelines. 19 LVM was calculated using ASE convention (LVM = 0.8 × [1.04 × (interventricular septum thickness + left ventricular diastolic diameter + PWT)3 − left ventricular diastolic diameter 3] + 0.6) and was indexed for body surface area (LVM index − LVMI) and also for height (m) 2.7 (LVMI-H). LVH was considered if LVMI was >115 g/m 2 for men and >95 g/ m 2 for women. RWT was calculated as (2 × PWT)/left ventricular diastolic diameter, with increased RWT defined as >0.42, from which geometric patterns (normal, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy) were derived. 19 Alternative evaluation of RWT was also calculated for descriptive purposes, using interventricular septum thickness + PWT/left ventricular diastolic diameter (since interventricular septum is more affected by increased afterload and myocardial abnormalities may be noticed before on interventricular septum than in the other LV walls). 20 LV ejection fraction was calculated using Simpson formula from apical views. LA volume was measured at ventricular systole, just before mitral valve opening, and calculated from apical 4-and 2-chamber views using biplane method of disks. LA diameter was measured in 2D parasternal view at the end of LV systole, between the leading edge of the posterior aortic wall and the leading edge of the posterior wall of the LA. LV diastolic function was evaluated with transmitral pulsed Doppler (peak E velocity, peak A velocity, E/A ratio, and deceleration time) and mitral annulus tissue Doppler velocity (early diastolic velocity-e' , late diastolic velocity-a'). LV diastolic function was classified according to recent guidelines. 21 Normal diastolic function was defined as: medial e' ≥7 cm/s, lateral e' ≥10 cm/s, and LA volume index <34 ml/m 2 , in the absence of pulmonary hypertension. 21 
Statistical methods
Comparisons between initial and final echocardiographic measurements were assessed by paired-samples t-test for continuous variables and Chi squared for categorical variables. One-way analysis of variance was used to compare variation of echocardiographic parameters with tertiles of BP variation, and post-hoc analysis for group differences was made using Bonferroni method. Intraobserver reproducibility was evaluated in 20 studies randomly chosen using intraclass correlation coefficient, and varied between 0.99 and 0.67, with the lower reproducibility for the posterior wall thickness measurement. Data analysis was performed with PASW Statistics 18. Data are expressed as mean ± SD. P <0.05 was considered statistically significant.
RESULTS
From the 655 participants of the PREVER-treatment study, 305 belonged to statewide centers coordinated by the Hospital de Clínicas de Porto Alegre center. The 230 participants from Hospital de Clínicas de Porto Alegre center were invited to participate of the echocardiographic evaluation, 133 participants were willing to participate, and 110 of these fulfilled inclusion criteria (Figure 1 ).
Baseline characteristics of participants of the echocardiographic study are shown in Table 1 . Mean age was 55 ± 8 years, 56.4% were male and 9% had diabetes. Mean body mass index was 28.5 kg/m 2 , and 34 individuals (30.9%) were obese. Mean SBP was 140.8 ± 7.3 mm Hg and diastolic BP (DBP) was 90.4 ± 5.7 mm Hg. Clinical characteristics of echocardiographic study participants did not differ from all Rio Grande do Sul state participants.
After 18 months of antihypertensive treatment, mean SBP was 129.7 ± 9.4 mm Hg (mean reduction of 11.1 mm Hg ± 10.4 mm Hg, P = 0.009) and DBP was 83.0 ± 6.9 mm Hg (mean reduction of 7.4 mm Hg ± 6.2 mm Hg, P < 0.001). At the final evaluation, there was a significant reduction in LA volume, LVM, interventricular septum thickness, posterior wall thickness, and RWT (Table 2) .
At baseline, 60.9% of the individuals were categorized as normal diastolic function, 20% as mild diastolic dysfunction, and 19.1% had indeterminate diastolic function, with no individual presenting with moderate/severe diastolic dysfunction. At the follow-up evaluation, there was no difference in the prevalence of individuals with normal diastolic function (P = 0.26; Table 2 ), neither with the other diastolic patterns. Also, there were no significant modifications in individual parameters of diastolic function, with the exception of an increase in deceleration time of E-wave.
LV geometric patterns analysis (Figure 2) showed that, at baseline, 60% of participants (n = 66) had concentric LV remodeling, which reduced to 42% (n = 46) at the end of the study (P = 0.007). This corresponded to a significant increase in the proportion of participants with normal LV geometry from 31% to 49% (P = 0.006).
There was variation of LVM, LVM index, and interventricular septum thickness according to tertiles of SBP reduction at the end of study (Table 3) . There was significant reduction in these parameters only in those with a reduction in SBP greater that 6.2 mm Hg. No significant change in echocardiographic parameters was seen when participants were stratified by the magnitude of DBP reduction (Table 4) . In an exploratory analysis investigating potential predictors of LVM reduction, there was no significant association between tertiles of LVM change with sex, age, skin color, or body mass index.
DISCUSSION
BP-lowering treatment of patients with stage I hypertension treated for 18 months reduced LVM and LA volume and increased the prevalence of a normal LV geometry due to concentric LV remodeling prevalence reduction.
The magnitude of BP reduction and of the LVM reduction are in accordance with the study TOHMS, one of the largest randomized studies comparing the effect of different antihypertensive medications on LVM in stage I hypertension. 22 In TOHMS, there was a LVM reduction of 34 g with chlorthalidone in 48 months. Our study showed a mean reduction of 6.8 g in only 18 months (5.3 g with chlorthalidone/ amiloride and 8.5 g with losartan), that would represent a similar effect size, assuming a linear and constant decrease in LVM dependent on continued treatment. Moreover, this effect could be detected relatively early after the introduction of antihypertensive treatment. The inference between treatment effect and LVM reduction was reinforced when we stratified for SBP reduction tertiles. There was no significant decrease in LVM when the SBP reduction was modest, nor with DBP reduction. In the LIFE trial, 23 systolic-but not diastolic-BP reduction was correlated with decrease in LVM in patients with stage II and III hypertension. In the Campania Salute Network study, 24 reduction in both SBP and DBP was associated with decrease in LVM in individuals with LVH at baseline. In our study, where individuals mostly presented with LV concentric remodeling instead of concentric hypertrophy, we had a similar reduction of SBP and DBP, but only SBP was associated with LVM reduction, suggesting that, in individuals with stage I hypertension and less severe hypertensive cardiac involvement, SBP correlates better with LVM reduction.
We had a higher prevalence of LV concentric remodeling at baseline than previous studies 4, 23, 25, 26 possibly for 2 reasons: our measurements were made using second harmonic 2D images instead of M-mode images, and we used ). An important finding is that, even in these patients with stage I hypertension, there was an increase in the prevalence of normal geometry after 18 months of antihypertensive treatment. Even minor changes in RWT are independently associated with cardiovascular events, and the persistence of a concentric geometry independently of LVM is associated with CV events. 9, 22, 27 No difference in parameters of diastolic function by transmitral Doppler and tissue Doppler of the mitral annulus between baseline and after 18 months of treatment was found. In individuals with resistant hypertension, 28 diastolic function showed improvement only in the third year of follow up, while LVM reduction was already seen in the first year of follow up. Another study, where individuals had similar BP but all already had diastolic dysfunction at baseline, 29 there was a significant improvement in pulsed lateral e' velocity after 38 weeks of antihypertensive treatment. Our results, in individuals with a milder stage of hypertensionand most of them with normal diastolic function on baseline-may suggest that structural changes precede detectable diastolic function parameters changes in early hypertension stages, and is in accordance with recent guidelines for diastolic function evaluation, that proposes a more specific and conservative approach to call for the presence of mild diastolic dysfunction. 21 Additionally, we found a decrease on LA volume and LA volume index, even though the great majority of our patients did not have LA enlargement on baseline. It complements a cohort study in stage I and II hypertension, 30 that found a reduction in LA volume after 1 year of treatment with telmisartan in patients with LVH and LA enlargement on baseline. Our study demonstrated that antihypertensive treatment also showed benefit in reducing LA volume in milder hypertensive individuals.
As potential limitations, echocardiographic data are originated from a single study center that, albeit having similar demographic characteristics of those who did not participate in the substudy, may not be representative of other investigation centers. Also, sample size was calculated for the original clinical trial, and was underpowered to detect smaller echocardiographic differences. However, our results are noteworthy, considering the expected low burden of target organ damage in this population, and the relatively small absolute magnitude of the intervention, for only 18 months.
CONCLUSIONS
In conclusion, antihypertensive treatment for 18 months has impact on echocardiographic indicators of hypertensive target organ damage, which are already present in a high proportion of patients with stage I hypertension. Reduction of LVM and LA volume, and decrease in prevalence of concentric LV remodeling are in accordance with other evidences of benefits from an intensive BP control in more severe hypertension. If maintained along the years, the beneficial effects over echocardiographic parameters will probably translate in reduction of clinical consequences of hypertensive cardiomyopathy, particularly of heart failure with preserved ejection fraction.
